Results 271 to 280 of about 236,667 (309)
Some of the next articles are maybe not open access.
British Journal of Haematology, 1991
Summary Of 38 patients with a Philadelphia‐chromosome positive chronic myeloid leukaemia treated with recombinant interferon alpha (rIFN‐α) 2a or 2b and monitored for emergence of IFN‐antibodies in their sera 11 patients developed rIFN‐α2 binding and 10 rIFN‐α2 neutralizing antibodies.
P V, Wussow +7 more
openaire +2 more sources
Summary Of 38 patients with a Philadelphia‐chromosome positive chronic myeloid leukaemia treated with recombinant interferon alpha (rIFN‐α) 2a or 2b and monitored for emergence of IFN‐antibodies in their sera 11 patients developed rIFN‐α2 binding and 10 rIFN‐α2 neutralizing antibodies.
P V, Wussow +7 more
openaire +2 more sources
Interferon alpha 2-b therapy of HCV and NonBNonC chronic hepatitis
1992Twenty-four patients with HCV and NonBNonC chronic hepatitis--4 with HIV coinfection--were treated with r-IFN alpha for at least six months. In this period 62.5% of patients show a normalization of ALT but not a sustained remission. Non-responders have histologically more severe and long-lasting chronic hepatitis.
M, Gargiulo +4 more
openaire +2 more sources
Neuroendocrine effects of interferon alpha 2-a in healthy human subjects.
Journal of biological regulators and homeostatic agents, 1990The acute effects of interferon alpha-2a (3 x 10 IU im) on catecholamine and immunoreactive beta endorphin plasma levels, cortisol serum levels and lymphocyte beta 2-adrenoceptor density were evaluated in ten healthy volunteers. Interferon induced a significant increase in plasma norepinephrine; there was an increased norepinephrine standing response ...
PENDE, ALDO +7 more
openaire +2 more sources
Vestnik otorinolaringologii, 1997
1-year or longer treatment of juvenile respiratory papillomatosis (JRP) with alpha-2 interferons (A21) leads to emergence of antibodies to A21 in 54.3% of the patients. The greatest percentage of the antibody positives (94.4%) was found among JRP patients treated with intramuscular recombinant human A21 (reaferon).
V D, Kol'tsov +4 more
openaire +1 more source
1-year or longer treatment of juvenile respiratory papillomatosis (JRP) with alpha-2 interferons (A21) leads to emergence of antibodies to A21 in 54.3% of the patients. The greatest percentage of the antibody positives (94.4%) was found among JRP patients treated with intramuscular recombinant human A21 (reaferon).
V D, Kol'tsov +4 more
openaire +1 more source
[Alpha 2 -interferon therapy in metastasizing malignant melanoma].
Deutsche medizinische Wochenschrift (1946), 1987Low doses of recombinant alpha 2-interferon were administered to 20 patients with stage III malignant melanoma. Dosage was 2.5 million IU intramuscularly daily in the first four weeks, then 2.5 million IU twice a week. The treatment was well tolerated, but there was no definitely demonstrable therapeutic effect.
M, Landthaler +3 more
openaire +1 more source
Effect of intralesional alpha 2-interferon on actinic keratoses.
Archives of dermatology, 1986The effect of intralesional alpha 2-interferon (IFN) on actinic keratoses was examined in this two-part study. In phase I, 11 of 12 lesions cleared following nine injections of IFN (5 X 10(5) IU per dose) compared with none of 12 keratoses injected with placebo. Smaller doses of IFN (1 X 10(5) IU and 1 X 10(4) IU per injection) produced clearing of 42%
L, Edwards +4 more
openaire +1 more source
Alpha-synuclein supports type 1 interferon signalling in neurons and brain tissue
Brain, 2022Tilo Kunath +2 more
exaly